Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Kintara Therapeutics Inc (KTRA)

Kintara Therapeutics Inc (KTRA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Kintara Therapeutics to Present at the LD Micro Main Event XVI Conference

/PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid...

KTRA : 0.1580 (+15.08%)
Kintara Therapeutics Presents Case Studies of Glioblastoma Patients Treated with VAL-083 at 2023 European Association for Neuro-Oncology Annual Meeting

/PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid...

KTRA : 0.1580 (+15.08%)
Kintara Therapeutics Announces Fiscal 2023 Year Financial Results and Provides Corporate Update

/PRNewswire/ -- Kintara Therapeutics, Inc. (NASDAQ: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid...

KTRA : 0.1580 (+15.08%)
Kintara Therapeutics to Present at the 2023 European Association for Neuro-Oncology Annual Meeting

/PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid...

KTRA : 0.1580 (+15.08%)
Kintara Therapeutics to Host Virtual KOL Event on VAL-083, A Potential First-in-Class Small Molecule Chemotherapeutic for Glioblastoma, on August 21, 2023

/PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid...

KTRA : 0.1580 (+15.08%)
Kintara Therapeutics to Present at the Emerging Growth Conference

/PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid...

KTRA : 0.1580 (+15.08%)
Kintara Therapeutics to Participate in the Fifth Annual Glioblastoma Awareness Day in Washington, D.C.

/PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid...

KTRA : 0.1580 (+15.08%)
Kintara Therapeutics Awarded $2.0 Million National Institutes of Health SBIR Grant to Support the Clinical Development of REM-001

/PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid...

KTRA : 0.1580 (+15.08%)
Kintara Therapeutics to Participate in the Maxim Group Virtual Healthcare Conference

/PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid...

KTRA : 0.1580 (+15.08%)
Kintara Therapeutics to Commemorate National Brain Tumor Awareness Month with Ringing the Bell at Nasdaq Closing Along with Global Coalition for Adaptive Research and the National Brain Tumor Society

/PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid...

KTRA : 0.1580 (+15.08%)

Barchart Exclusives

Guess vs. Levi Strauss: Which Breakout Dividend Stock Is a Better Buy?
With Levi Strauss and Guess stock prices surging and both apparel giants impressing shareholders with their dividend payments, which of the two is a better buy? Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar